Cargando…
Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies
Gene editing protocols often require the use of a subcloning step to isolate successfully edited cells, the behavior of which is then compared to the aggregate parental population and/or other non-edited subclones. Here we demonstrate that the inherent functional heterogeneity present in many cell l...
Autores principales: | Olive, Jessica F., Qin, Yuanbo, DeCristo, Molly J., Laszewski, Tyler, Greathouse, Frances, McAllister, Sandra S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999218/ https://www.ncbi.nlm.nih.gov/pubmed/29897959 http://dx.doi.org/10.1371/journal.pone.0198790 |
Ejemplares similares
-
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
por: Ubellacker, Jessalyn M., et al.
Publicado: (2017) -
Using CRISPR-Cas9-mediated genome editing to generate C. difficile mutants defective in selenoproteins synthesis
por: McAllister, Kathleen N., et al.
Publicado: (2017) -
What is CRISPR/Cas9?
por: Redman, Melody, et al.
Publicado: (2016) -
Advances in CRISPR/Cas9
por: Zhu, Youmin
Publicado: (2022) -
The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System
por: Qiao, Huanhuan, et al.
Publicado: (2021)